

BioMed Realty Trust Inc  
Form 424B7  
June 18, 2008

Filed pursuant to Rule 424(b)(7)  
SEC File No. 333-139827

**PROSPECTUS SUPPLEMENT NO. 6  
(To Prospectus dated January 5, 2007)**

**514,446 Shares  
BioMed Realty Trust, Inc.  
Common Stock**

**Issuable upon Exchange of BioMed Realty, L.P. 4.50% Exchangeable Senior Notes due 2026**

This prospectus supplement no. 6 supplements and amends the prospectus dated January 5, 2007, relating to the resale from time to time by certain selling stockholders of shares of our common stock that may be issued upon the exchange or redemption of BioMed Realty, L.P.'s 4.50% Exchangeable Senior Notes due 2026.

You should read this prospectus supplement no. 6 in conjunction with the prospectus. This prospectus supplement no. 6 is not complete without, and may not be delivered or used except in conjunction with, the prospectus, including any amendments or supplements to it. This prospectus supplement no. 6 is qualified by reference to the prospectus, except to the extent that the information provided by this prospectus supplement no. 6 supersedes information contained in the prospectus.

Selling stockholders, including their transferees, pledgees or donees or their successors, may from time to time offer and sell pursuant to the prospectus and any accompanying prospectus supplement any or all of the shares of our common stock which we may issue upon the exchange or redemption of the notes.

The following table sets forth information, as of June 18, 2008, with respect to the selling stockholders and the number of shares of our common stock that would become beneficially owned by each stockholder should we issue our common stock to such selling stockholder that may be offered pursuant to this prospectus upon the exchange or redemption of the notes. The information is based on information provided by or on behalf of the selling stockholders. The selling stockholders may offer all, some or none of the shares of our common stock which we may issue upon the exchange or redemption of the notes. Because the selling stockholders may offer all or some portion of such shares of our common stock, we cannot estimate the number of shares of our common stock that will be held by the selling stockholders upon termination of any of these sales. In addition, the selling stockholders identified below may have sold, transferred or otherwise disposed of all or a portion of their notes or shares of our common stock since the date on which they provided the information regarding their notes in transactions exempt from the registration requirements of the Securities Act of 1933, as amended.

The number of shares of our common stock issuable upon the exchange or redemption of the notes shown in the table below assumes exchange of the full amount of notes held by each selling stockholder at the maximum exchange rate of 31.7561 shares of our common stock per \$1,000 principal amount of notes and a cash payment in lieu of any fractional share. This exchange rate is subject to adjustment in certain events. Accordingly, the number of shares of our common stock issued upon the exchange or redemption of the notes may increase or decrease from time to time. The number of shares of our common stock owned by the other selling stockholders or any future transferee from any such holder assumes that they do not beneficially own any shares of common stock other than the common stock that we may issue to them upon the exchange or redemption of the notes.

Based upon information provided by the selling stockholders, none of the selling stockholders identified below nor any of their affiliates, officers, directors or principal equity holders has held any positions or office or has had any material relationship with us within the past three years.

To the extent any of the selling stockholders identified below are broker-dealers, they may be deemed to be, under interpretations of the staff of the Securities and Exchange Commission, underwriters within the meaning of the Securities Act of 1933, as amended.

<b>Name</b>	<b>Number of Shares Beneficially Owned Prior to the Offering</b>	<b>Percentage of Shares Beneficially Owned Prior to the Offering(1)</b>	<b>Number of Shares Offered Hereby</b>	<b>Number of Shares Beneficially Owned After the Offering(2)</b>	<b>Percentage of Shares Beneficially Owned After the Offering(1)(2)</b>
Basso Fund Ltd.(3)	5,716	*	5,716		*
Basso Holdings Ltd.(4)	105,271	*	105,271		*
Basso Multi-Strategy Holding Fund Ltd.(5)	63,670	*	63,670		*
CNH CA Master Account, L.P.(6)	22,229	*	22,229		*
Highbridge Convertible Arbitrage Master Fund, L.P.(7)	63,512	*	63,512		*
Highbridge International LLC(7)	254,048	*	254,048		*
<b>Total</b>	<b>514,446</b>	<b>*</b>	<b>514,446</b>		<b>*</b>

\* Less than 1%.

(1) Based on a total of 71,722,258 shares of our common stock outstanding as of June 18, 2008.

(2) Assumes the selling stockholder sells all of its shares of our common stock offered pursuant to this prospectus.

(3) Basso Capital Management, L.P. is the investment manager to Basso Fund Ltd. Howard Fischer is a managing

member of  
Basso GP LLC,  
the general  
partner of Basso  
Capital  
Management,  
L.P. Mr. Fischer  
has ultimate  
responsibility  
for trading with  
respect to Basso  
Fund Ltd.

(4) Basso Capital  
Management,  
L.P. is the  
investment  
manager to  
Basso Holdings  
Ltd. Howard  
Fischer is a  
managing  
member of  
Basso GP LLC,  
the general  
partner of Basso  
Capital  
Management,  
L.P. Mr. Fischer  
has ultimate  
responsibility  
for trading with  
respect to Basso  
Holdings Ltd.

(5) Basso Capital  
Management,  
L.P. is the  
investment  
manager to  
Basso  
Multi-Strategy  
Holding Fund  
Ltd. Howard  
Fischer is a  
managing  
member of  
Basso GP LLC,  
the general  
partner of Basso  
Capital

Management,  
L.P. Mr. Fischer  
has ultimate  
responsibility  
for trading with  
respect to Basso  
Multi-Strategy  
Holding Fund  
Ltd.

(6) CNH Partners,  
LLC serves as  
investment  
adviser with  
sole power to  
direct  
investments and  
sole power to  
vote the shares  
of CNH CA  
Master Account,  
L.P., and Robert  
Krail, Mark  
Mitchell and  
Todd Pulvino  
are investment  
principals of  
CNH Partners,  
LLC.

(7) Highbridge  
Capital  
Management,  
LLC is the  
trading manager  
of each of  
Highbridge  
Convertible  
Arbitrage  
Master Fund,  
L.P. and  
Highbridge  
International  
LLC and has  
voting control  
and investment  
discretion over  
the securities  
held by each of  
Highbridge  
Convertible

Arbitrage  
Master Fund,  
L.P. and  
Highbridge  
International  
LLC. Glenn  
Dubin and  
Henry Swieca  
control  
Highbridge  
Capital  
Management,  
LLC and have  
voting control  
and investment  
discretion over  
the securities  
held by each of  
Highbridge  
Convertible  
Arbitrage  
Master Fund,  
L.P. and  
Highbridge  
International  
LLC. Each of  
Highbridge  
Capital  
Management,  
LLC, Glenn  
Dubin and  
Henry Swieca  
disclaims  
beneficial  
ownership of  
the securities  
held by  
Highbridge  
Convertible  
Arbitrage  
Master Fund,  
L.P. or  
Highbridge  
International  
LLC.

**You should consider the risks that we have described in Risk Factors beginning on page 2 of the prospectus and included in our periodic reports and other information that we file with the Securities and Exchange Commission before investing in our securities.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the prospectus or this prospectus supplement no. 6. Any representation to the contrary is a criminal offense.**

Edgar Filing: BioMed Realty Trust Inc - Form 424B7

The date of this prospectus supplement no. 6 is June 18, 2008.

2